307 related articles for article (PubMed ID: 34970268)
21. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer.
Liu C; Chen B; Huang Z; Hu C; Jiang L; Zhao C
Int Immunopharmacol; 2020 Dec; 89(Pt B):107074. PubMed ID: 33049494
[TBL] [Abstract][Full Text] [Related]
23. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
24. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
[TBL] [Abstract][Full Text] [Related]
25. A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients.
Liu Z; Yang H; Chen Z; Jing C
Hereditas; 2022 Oct; 159(1):40. PubMed ID: 36253800
[TBL] [Abstract][Full Text] [Related]
26. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
27. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma.
Tao Y; Liang B
Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.
Chen T; Yang C; Dou R; Xiong B
Cancer Med; 2021 Sep; 10(18):6546-6560. PubMed ID: 34382341
[TBL] [Abstract][Full Text] [Related]
29. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
30. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
31. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
32. Development and verification of a newly established cuproptosis-associated lncRNA model for predicting overall survival in uterine corpus endometrial carcinoma.
Hu P; Wang Y; Chen X; Zhao L; Qi C; Jiang G
Transl Cancer Res; 2023 Aug; 12(8):1963-1979. PubMed ID: 37701111
[TBL] [Abstract][Full Text] [Related]
33. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
34. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
35. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
Biochem Genet; 2023 Dec; ():. PubMed ID: 38108937
[TBL] [Abstract][Full Text] [Related]
36. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
37. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
38. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
39. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
40. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]